Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06759649 · ClinicalTrials.gov registry record · Phase 1

A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies

A Phase 1 study of Neoplasm and Cancer, Malignant Tumors, sponsored by Compugen.

Recruiting
Registry status
Phase 1
Development phase
200
Enrollment target
11
Study locations

NCT06759649 is a Phase 1 study of Neoplasm and Cancer, Malignant Tumors that is actively recruiting participants, run by Compugen. The registered enrollment target is 200 participants, roughly in line with the 184-participant average among 11 other Neoplasm trials with a reported enrollment target. The trial reports 11 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06759649, a Phase 1 study of Neoplasm and Cancer, Malignant Tumors, is actively recruiting participants, sponsored by Compugen.

RECRUITING
Registry status
Phase 1
Development phase
200 participants
Enrollment target
11
Study locations

Study Summary

The overall goal of this first-in-human (FIH) clinical trial is to learn about the safety and dosing of COM503 when given alone or in combination with zimberelimab in participants with advanced solid tumors. The primary objectives of this study are: * To assess the safety and tolerability of COM503 as monotherapy and COM503 in combination with zimberelimab in participants with advanced solid tumors. * To identify the maximum tolerated dose (MTD) / maximum administered dose (MAD) and/or the recommended phase 2 dose (RP2D) of COM503 as monotherapy and in combination with zimberelimab in participants with advanced solid tumors.

Conditions Studied

Neoplasm Cancer, Malignant Tumors

Interventions

  • DRUG Zimberelimab
  • DRUG COM503

Study Locations (11)

Israel

  • Rambam Health Care Campus - Haifa
  • Hadassah University Medical Center- Ein Kerem - Jerusalem
  • Rabin Medical Center - Petah Tikva
  • The Chaim Sheba Medical Center - Ramat Gan

Texas

  • NEXT Oncology San Antonio - San Antonio
  • START - San Antonio

Connecticut

  • Yale- New Haven Hospital- Yale Cancer Center - New Haven

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston

Michigan

  • START Midwest - Grand Rapids

Tennessee

  • The West Clinic, PLCC dba West Cancer Center - Germantown

Virginia

  • NEXT Oncology Virginia - Fairfax

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2025-01-07
Est. Completion 2027-11-22
Phase Phase 1

Sponsor

Compugen

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06759649

The ClinicalTrials.gov registry entry for NCT06759649 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 184-participant average among 11 other Neoplasm trials with a reported enrollment target. The listed sponsor is Compugen, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Zimberelimab is the first listed.

NCT06759649 reports 11 study locations spanning 7 distinct geographic areas - top geographies include Israel, Texas, Connecticut.

Frequently Asked Questions

What is clinical trial NCT06759649 about?

NCT06759649 is a clinical study titled "A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies". The overall goal of this first-in-human (FIH) clinical trial is to learn about the safety and dosing of COM503 when given alone or in combination with zimberelimab in participants with advanced solid tumors. The primary objectives of this study are: * To assess the safety and tolerability of COM50...

What is the current status of trial NCT06759649?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2025-01-07. Estimated completion is 2027-11-22.

What conditions does trial NCT06759649 study?

This clinical trial studies the following conditions: Neoplasm, Cancer, Malignant Tumors.

What interventions are being tested in trial NCT06759649?

The interventions under investigation include: Zimberelimab (DRUG), COM503 (DRUG).

Who is sponsoring clinical trial NCT06759649?

This trial is sponsored by Compugen, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06759649 being conducted?

This trial has 11 study locations across Connecticut, Massachusetts, Michigan, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neoplasm

All registered trials for this condition

Cancer, Malignant Tumors

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.